Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

By Yood Marianne Ulcickas   Oliveria Susan A.   Cziraky Mark   Hirji Ishan   Hamdan Muhammad   Davis Catherine  

Current Medical Research and Opinion, Vol. 28, Iss. 2, 2012-02 ,pp. : 213-219

Informa Healthcare

Access to resources Recommend Favorite

Nilotinib Can Override Dasatinib Resistance in Chronic Myeloid Leukemia Patients with Secondary Resistance to Imatinib First-Line Therapy

By  

Acta Haematologica, Vol. 118, Iss. 3, 2007-09 ,pp. : 162-164

Karger

Access to resources Recommend Favorite

Isodicentric Philadelphia Chromosome: A Rare Chromosomal Aberration in Imatinib-Resistant Chronic Myelogenous Leukemia Patients - Case Report with Review of the Literature

By  

Cytogenetic and Genome Research, Vol. 150, Iss. 3-4, 2017-03 ,pp. : 273-280

Karger

Access to resources Recommend Favorite

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib

By Goldberg Stuart L.   Chen Lei   Guerin Annie   Macalalad Alexander R.   Liu Nathan   Kaminsky Michael   Ericson Solveig G.   Wu Eric Q.  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1075-1082

Informa Healthcare

Access to resources Recommend Favorite

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia

By Wu Eric Q.   Guerin Annie   Yu Andrew P.   Bollu Vamsi K.   Guo Amy   Griffin James D.  

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2861-2869

Informa Healthcare

Access to resources Recommend Favorite